Search

You searched for "macular degeneration"

16 results found

Clinical relevance of the anatomic classification of neovascular age-related macular degeneration

1 February 2018 | | Imaging, Retina / Uvea / Vitreous, Ophthalmology
The author explains why an OCT-based classification of neovascular AMD is needed and how these neovascular subtypes may help to predict patients’ long-term visual outcome. Age-related macular degeneration (AMD) is a chronic and progressive neurodegenerative process involving the macula in...

More sensitive visual acuity test for age-related macular degeneration

1 October 2016 | | Retina / Uvea / Vitreous
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

RSM: Medicine and Me-Living with age related macular degeneration

13 July 2020 -13 June 2020

10th Moorfields International Glaucoma Symposium (MIGS) 2018

28 January 2018 -29 January 2018
By Sofia Rokerya, MBBS, MRCOphth, FRCSI Speakers at MIGS (L-R) Subash Suthar, Divya Mathews, Sajjad Ahmed, Dan Lindfield and Boris Malyugin. This two-day international conference encompassed various subjects pertinent to glaucoma. After the welcome brief was extended by hosts Keith...

Can OCT predict Alzheimer’s disease?

5 February 2020 | | Ophthalmology, Optometry, Imaging
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Can OCT predict Alzheimer’s disease? In 1986 Hinton et al. demonstrated evidence of optic nerve degeneration...

Sharing best practice and landmark evidence in glaucoma care

1 August 2019 | | Ophthalmology, Glaucoma
Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...

An interview with Professor John Forrester

2 December 2019 | | Ophthalmology
What made you choose ophthalmology as a career and how did your interest in academia develop? During Medical School at Glasgow University, I was getting progressively disillusioned with the career options while my colleagues and friends all seemed to quickly...

Pathophysiology of diabetic macular oedema: why combination therapy may be better

1 October 2015 | | Retina / Uvea / Vitreous
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

The role of inflammation in the pathophysiology of DMO

1 February 2016 | | Retina / Uvea / Vitreous
Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...

National OCT Conference

19 November 2017 -20 November 2017
The third National OCT Conference took place at the Hilton London Paddington last November, attracting in excess of 300 delegates. The conference programme was filled with thought-provoking lectures and clinical workshops, all of which were fully booked, despite a significant...

Stem cell therapy for Parkinson’s disease: researching for an 
effective cure

1 December 2015 | | Neuro-Ophthalmology
Neurodegenerative diseases are characterised by the chronic and progressive loss of neurons, which in turn results in loss of cognitive and physical functions. The World Health Organization has estimated that the disability-adjusted life years lost from neurological disease was about...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

1 April 2016 | | Cataract and Refractive, Cornea / External Eye Disease, Genetics, Glaucoma, Imaging, Neuro-Ophthalmology, Ocular Pathology and Oncology, Oculoplastics, Ophthalmology, Optometry, Orbit, Paediatric Ophthalmology / Strabismus, Retina / Uvea / Vitreous
The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...
  • 1 (current)
  • 2